Literature DB >> 20661184

Kinsenoside isolated from Anoectochilus formosanus suppresses LPS-stimulated inflammatory reactions in macrophages and endotoxin shock in mice.

Hung-Bo Hsiao1, Jin-Bin Wu, Ho Lin, Wen-Chuan Lin.   

Abstract

In the present study, we reported that kinsenoside, a major component of Anoectochilus formosanus, inhibited inflammatory reactions in mouse peritoneal lavage macrophages and protects mice from endotoxin shock. In LPS-stimulated mouse peritoneal lavage macrophages, kinsenoside inhibited the inflammatory mediators, such as nitric oxide, TNF-[alpha], IL-1[beta], monocyte chemoattractant protein 1, and macrophage migration inhibitory factor production. Furthermore, kinsenoside decreased the formation of a nuclear factor [kappa]B-DNA complex and nuclear p65 and p50 protein levels. Kinsenoside inhibited nuclear factor [kappa]B translocation through both I[kappa]B[alpha]-dependent and -independent pathway. In contrast, it stimulated anti-inflammatory cytokine IL-10 generation and enhanced the mRNA expression of IL-10 and suppressor of cytokine signaling 3 in the same cells induced by LPS. In an animal model, both pretreatment and posttreatment of kinsenoside increased the survival rate of ICR mice challenged by LPS (80 mg/kg, i.p.). Pretreatment with kinsenoside decreased serum levels of TNF-[alpha], IL-1[beta], IL-10, monocyte chemoattractant protein 1, and migration inhibitory factor at 1 h after sublethal dose of LPS (40 mg/kg, i.p.) in mice. In contrast, kinsenoside enhanced serum IL-10 level at 24 h after LPS injection in mice. In conclusion, kinsenoside inhibited the production of inflammatory mediators and enhanced anti-inflammatory cytokine generation. Therefore, kinsenoside can alleviate acute inflammatory hazards.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20661184     DOI: 10.1097/SHK.0b013e3181f0e7a3

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  16 in total

Review 1.  Kinsenoside: A Promising Bioactive Compound from Anoectochilus Species.

Authors:  Chang-Xing Qi; Qun Zhou; Zhou Yuan; Zeng-Wei Luo; Chong Dai; Hu-Cheng Zhu; Chun-Mei Chen; Yong-Bo Xue; Jian-Ping Wang; Ya-Fen Wang; Ya-Ping Liu; Ming Xiang; Wei-Guang Sun; Jin-Wen Zhang; Yong-Hui Zhang
Journal:  Curr Med Sci       Date:  2018-03-15

2.  Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways.

Authors:  H-B Hsiao; H Lin; J-B Wu; W-C Lin
Journal:  Osteoporos Int       Date:  2012-11-10       Impact factor: 4.507

3.  Kinsenoside inhibits the inflammatory mediator release in a type-II collagen induced arthritis mouse model by regulating the T cells responses.

Authors:  Hung-Bo Hsiao; Chang-Chi Hsieh; Jin-Bin Wu; Ho Lin; Wen-Chuan Lin
Journal:  BMC Complement Altern Med       Date:  2016-02-25       Impact factor: 3.659

4.  Anti-inflammatory and anti-insulin resistance activities of aqueous extract from Anoectochilus burmannicus.

Authors:  Phatcharaporn Budluang; Pornsiri Pitchakarn; Pisamai Ting; Piya Temviriyanukul; Ariyaphong Wongnoppawich; Arisa Imsumran
Journal:  Food Sci Nutr       Date:  2016-08-26       Impact factor: 2.863

5.  Kinsenoside screening with a microfluidic chip attenuates gouty arthritis through inactivating NF-κB signaling in macrophages and protecting endothelial cells.

Authors:  Qiao Han; Wang Bing; Yin Di; Li Hua; Li Shi-He; Zheng Yu-Hua; Han Xiu-Guo; Wang Yu-Gang; Fan Qi-Ming; Yang Shih-Mo; Tang Ting-Ting
Journal:  Cell Death Dis       Date:  2016-09-01       Impact factor: 8.469

6.  Oral Bioavailability of Kinsenoside in Beagle Dogs Measured by LC-MS/MS: Improvement of Ex Vivo Stability of a Lactone-Containing Compound.

Authors:  Xin Zhang; Ming Jin; Yuping Liu; Qimingxing Chen; Luqin Si; Gao Li; Yonghui Zhang; Jiangeng Huang
Journal:  Pharmaceutics       Date:  2018-07-09       Impact factor: 6.321

7.  In Vitro Assessment of CYP-Mediated Drug Interactions for Kinsenoside, an Antihyperlipidemic Candidate.

Authors:  Shaheed Ur Rehman; Min Sun Choi; In Sook Kim; Zengwei Luo; Yongbo Xue; Guangming Yao; Yonghui Zhang; Hye Hyun Yoo
Journal:  Molecules       Date:  2016-06-18       Impact factor: 4.411

8.  Kinsenoside Alleviates 17α-Ethinylestradiol-Induced Cholestatic Liver Injury in Rats by Inhibiting Inflammatory Responses and Regulating FXR-Mediated Bile Acid Homeostasis.

Authors:  Jiaxiong Ming; Qianqian Xu; Limin Gao; Yanfang Deng; Jie Yin; Qun Zhou; Qingyi Tong; Yonghui Zhang
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-11

Review 9.  Preventively enteral application of immunoglobulin enriched colostrums milk can modulate postoperative inflammatory response.

Authors:  Klaus Orth; Wolfram Trudo Knoefel; Martijn van Griensven; Christiane Matuschek; Matthias Peiper; Holger Schrumpf; Peter Arne Gerber; Wilfried Budach; Edwin Bölke; Bettina Alexandra Buhren; Matthias Schauer
Journal:  Eur J Med Res       Date:  2013-11-23       Impact factor: 2.175

10.  Kinsenoside ameliorates intervertebral disc degeneration through the activation of AKT-ERK1/2-Nrf2 signaling pathway.

Authors:  Yanqiu Wang; Rui Zuo; Ziwen Wang; Liwen Luo; Junlong Wu; Chao Zhang; Minghan Liu; Chunmeng Shi; Yue Zhou
Journal:  Aging (Albany NY)       Date:  2019-09-23       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.